Deucrictibant + Placebo + Deucrictibant + Placebo + Deucrictibant
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Conditions
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Trial Timeline
Oct 16, 2025 → Jun 1, 2027
NCT ID
NCT07266805About Deucrictibant + Placebo + Deucrictibant + Placebo + Deucrictibant
Deucrictibant + Placebo + Deucrictibant + Placebo + Deucrictibant is a phase 3 stage product being developed by Pharvaris for Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07266805. Target conditions include Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH).
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07266805 | Phase 3 | Recruiting |
Competing Products
20 competing products in Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)